Overview
Tesamorelin is classified as a ghrh analog peptide. Visceral fat reduction, body recomposition.
Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
Also known as: Egrifta
Category
GHRH Analog
Half-Life
0.43h
Route
SubQ
FDA Status
Approved
How Does Tesamorelin Work?
Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
At the molecular level, Tesamorelin operates through pathways characteristic of the GHRH Analog class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Tesamorelin visceral fat reduction (FDA trial)
Falutz et al. (JAMA): Randomized, double-blind, placebo-controlled Phase 3 trial showing 15.2% reduction in visceral adipose tissue vs. 5% increase in placebo. FDA-approved indication.
Evidence: very strong[2]Tesamorelin 52-week extension study sustained VAT reduction
Falutz et al. (J. Clin. Endocrinol. Metab.): 52-week data confirming sustained 18% visceral fat reduction with continuous therapy, with reversal upon discontinuation.
Evidence: strong[3]Tesamorelin reduces liver fat in HIV lipodystrophy
Stanley et al. (Ann. Intern. Med.): RCT demonstrating tesamorelin reduces hepatic fat content in HIV-infected patients with abdominal fat accumulation.
Evidence: strong[4]Tesamorelin improves executive function in older adults
Baker et al.: GHRH treatment (tesamorelin) shows favorable effects on executive function and verbal memory in cognitively normal and mildly impaired older adults via IGF-1 elevation.
Evidence: moderate[5]Tesamorelin IGF-1 effects and body composition (Phase 3)
Phase 3 trial showing ~80% increase in IGF-1 levels, improved body image distress scores, and significant trunk fat reduction across multiple patient populations.
Evidence: strongSafety Profile
FDA-approved for lipodystrophy; GI side effects possible. Contraindicated in active malignancy.
| Side Effect | Incidence | Severity |
|---|---|---|
| Fluid retention | ~15% of users | mild |
| Injection site reactions | ~12% of users | mild |
| Joint pain / arthralgia | ~8% of users | mild |
| Glucose elevation | ~5% of users | moderate |
Sourcing Tesamorelin for Research
If you're looking to source Tesamorelin for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Tesamorelin — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.